This announcement is a separate document:
百奥泰 自愿披露关于BAT2206（乌司奴单抗）注射液上市许可申请获得美国FDA和欧洲EMA受理的公告
Bio-Thera Solutions voluntarily disclosed the announcement about the acceptance of the application for the marketing authorization of BAT2206 (Ustekinumab Injection) by the US FDA and the European Medicines Agency (EMA).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.